Literature DB >> 7761479

Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity.

K Bhol1, K Natarajan, N Nagarwalla, A Mohimen, V Aoki, A R Ahmed.   

Abstract

Pemphigus vulgaris (PV) is a rare, potentially fatal, autoimmune disease that affects the skin and mucous membranes. The PV antigen (PVA) has been characterized as desmoglein 3. PV patients carry HLA-DR4- or HLA-DR6-bearing extended haplotypes. We recently demonstrated that patients with active disease have high titers of PV autoantibodies of the IgG1 and IgG4 subclasses. Patients in remission, healthy unaffected relatives, and some MHC-matched normal individuals have low levels of PV autoantibodies, which are IgG1 only. Furthermore, intraperitoneal injection of IgG from patients with active disease caused clinical disease in mice, but IgG from patients in remission, healthy relatives, or MHC-matched normal individuals did not. We prepared 12 peptides of 30 amino acids each (peptides Bos 1-12) spanning the extracellular domain of PVA. Patients with active disease recognize peptides Bos 1 and Bos 6 with high titers of IgG1 and IgG4 autoantibodies. Patients in remission have IgG1 autoantibodies to peptide Bos 1 only, in statistically significantly lower titers (P < 0.01). They no longer have IgG4 subclass autoantibodies to peptide Bos 6. Healthy relatives and normal unrelated individuals have low levels of only IgG1 autoantibodies that recognize only Bos 1. In vitro studies indicate that Bos 6-specific IgG and, to a lesser extent, Bos 1-specific IgG can cause acantholysis. Our data suggest that Bos 6-specific IgG4 is probably the main acantholytic autoantibody, while Bos 1-specific IgG4 may act as a facilitator or enhancer of the process. In this study we illustrate some of the paradigms that demonstrate the interactions between the MHC, subclass of autoantibodies, and peptide specificities of the autoantibodies in the autoimmune process. Thus, PV provides an important model to study the pathogenesis of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7761479      PMCID: PMC41884          DOI: 10.1073/pnas.92.11.5239

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

Review 1.  Determinant spreading and the dynamics of the autoimmune T-cell repertoire.

Authors:  P V Lehmann; E E Sercarz; T Forsthuber; C M Dayan; G Gammon
Journal:  Immunol Today       Date:  1993-05

2.  Immunoblot assay to study the pemphigus vulgaris antigen in normal human epidermis and COLO-16 cell line.

Authors:  A Mohimen; A R Ahmed
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

3.  Anti-intercellular substance antibodies. Presence in serum samples of 14 patients without pemphigus.

Authors:  A R Ahmed; S Workman
Journal:  Arch Dermatol       Date:  1983-01

4.  Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease.

Authors:  G J Anhalt; R S Labib; J J Voorhees; T F Beals; L A Diaz
Journal:  N Engl J Med       Date:  1982-05-20       Impact factor: 91.245

5.  Affinity immunoblotting studies on the restriction of autoantibodies from endemic pemphigus foliaceus patients.

Authors:  N J Calvanico; S J Swartz; L A Diaz
Journal:  J Autoimmun       Date:  1993-04       Impact factor: 7.094

6.  Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic.

Authors:  M Amagai; S Karpati; R Prussick; V Klaus-Kovtun; J R Stanley
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

7.  Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen.

Authors:  P V Lehmann; T Forsthuber; A Miller; E E Sercarz
Journal:  Nature       Date:  1992-07-09       Impact factor: 49.962

8.  Correlation of subclasses of IgG with disease activity in pemphigus vulgaris.

Authors:  K Bhol; A Mohimen; A R Ahmed
Journal:  Dermatology       Date:  1994       Impact factor: 5.366

9.  Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis.

Authors:  G J Giudice; K C Wilske; G J Anhalt; J A Fairley; A F Taylor; D J Emery; R G Hoffman; L A Diaz
Journal:  J Invest Dermatol       Date:  1994-06       Impact factor: 8.551

10.  Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells.

Authors:  F D de Hon; M Ehlers; S Rose-John; S B Ebeling; H K Bos; L A Aarden; J P Brakenhoff
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more
  33 in total

1.  Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses.

Authors:  N Sami; K C Bhol; A R Ahmed
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

Review 2.  Maintenance and loss of self-tolerance in B cells.

Authors:  A Iglesias
Journal:  Springer Semin Immunopathol       Date:  2001-12

3.  Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection.

Authors:  Sarah K Browne; Rifat Zaman; Elizabeth P Sampaio; Kamonwan Jutivorakool; Lindsey B Rosen; Li Ding; Minjal J Pancholi; Lauren M Yang; Debra Long Priel; Gulbu Uzel; Alexandra F Freeman; Carlton E Hayes; Roger Baxter; Stuart H Cohen; Steven M Holland
Journal:  Blood       Date:  2012-03-08       Impact factor: 22.113

Review 4.  [Bullous autoimmune dermatoses. 2: Pathogenesis].

Authors:  M Hertl; G Schuler
Journal:  Hautarzt       Date:  2002-04       Impact factor: 0.751

5.  Determination of human anticytokine autoantibody profiles using a particle-based approach.

Authors:  Li Ding; Allen Mo; Kamonwan Jutivorakool; Minjal Pancholi; Steven M Holland; Sarah K Browne
Journal:  J Clin Immunol       Date:  2011-12-06       Impact factor: 8.317

Review 6.  Non-infectious environmental antigens as a trigger for the initiation of an autoimmune skin disease.

Authors:  Ye Qian; Donna A Culton; Joseph S Jeong; Nicole Trupiano; Jesus G Valenzuela; Luis A Diaz
Journal:  Autoimmun Rev       Date:  2016-07-08       Impact factor: 9.754

Review 7.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

8.  Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab.

Authors:  Alice Cho; Bridget Bradley; Robert Kauffman; Lalita Priyamvada; Yevgeniy Kovalenkov; Ron Feldman; Jens Wrammert
Journal:  JCI Insight       Date:  2017-06-15

9.  Possible role of natural killer cells in pemphigus vulgaris - preliminary observations.

Authors:  J N H Stern; D B Keskin; N Barteneva; J Zuniga; E J Yunis; A R Ahmed
Journal:  Clin Exp Immunol       Date:  2008-03-28       Impact factor: 4.330

10.  Divergent Specificity Development of IgG1 and IgG4 Autoantibodies in Endemic Pemphigus Foliaceus (Fogo Selvagem).

Authors:  Mike Maldonado; Luis A Diaz; Phillip Prisayanh; Jinsheng Yang; Bahjat F Qaqish; Valeria Aoki; Gunter Hans-Filho; Evandro A Rivitti; Donna A Culton; Ye Qian
Journal:  Immunohorizons       Date:  2017-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.